Less than a week after making a regulatory submission for a $1 million capital raise, prostate health company ProUroCare Medical, based in Eden Prairie, Minnesota, announced that it has secured market ...
Transrectal ultrasound guided (TRUS) biopsy has been the gold standard for prostate cancer diagnosis, but carries a significant risk of urinary tract infection, sometimes requiring hospital admission ...
Industry trade associations made the case for revisions to draft guidance on clinical testing recommendations for prostate tissue ablation devices in comments earlier this month. The Medical Imaging & ...
The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) issued draft guidance Tuesday to support clinical testing of high-intensity ultrasound systems for ...
Wisconsin-based medtech Rivermark Medical has secured $20m in a Series D financing round – supporting the company’s late-stage clinical activities being used for approval of its flagship device for ...
Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...
The MarketWatch News Department was not involved in the creation of this content. Oxford, UK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Topical summits in Dubai, Berlin, Nanjing, Basel, Lisbon, London and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results